Expert consensus document from the European Society of Cardiology on catheter-based renal denervation

F Mahfoud, TF Lüscher, B Andersson… - European Heart …, 2013 - academic.oup.com
Hypertension is highly prevalent and one of the most frequent chronic diseases worldwide. 1
It has been suggested that over the next two decades up to 50% of the adult population will …

Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension

F Mahfoud, C Ukena, RE Schmieder, B Cremers… - Circulation, 2013 - Am Heart Assoc
Background—Catheter-based renal sympathetic denervation (RDN) reduces office blood
pressure (BP) in patients with resistant hypertension according to office BP. Less is known …

Eligibility for percutaneous renal denervation: the importance of a systematic screening

WL Verloop, EE Vink, M Voskuil, E Vonken… - Journal of …, 2013 - journals.lww.com
Objective: Percutaneous renal denervation (pRDN) is a new and promising therapy for
resistant hypertension. Among patients suspected of having resistant hypertension, the …

Association of vitamin D status and blood pressure response after renal denervation

J Pöss, F Mahfoud, C Ukena, MD Esler… - Clinical Research in …, 2014 - Springer
Background Vitamin D deficiency is associated with hypertension; however, it is unclear
whether vitamin D influences therapeutic blood pressure reduction. Renal sympathetic …

Criteria from the Deutsche Gesellschaft für Kardiologie, Deutschen Hochdruckliga eV DHL®/Deutschen Gesellschaft für Hypertonie und Prävention and the …

F Mahfoud, O Vonend, U Kintscher, S Ewen, J Floege… - Der Kardiologe, 2013 - Springer
Zusammenfassung Dieses Positionspapier ist eine Stellungnahme der Deutschen
Gesellschaft für Kardiologie–Herz-und Kreislaufforschung eV, der Deutschen Gesellschaft …

Renal sympathetic denervation: does reduction of left ventricular mass improve functional myocardial parameters? A cardiovascular magnetic resonance imaging pilot …

M Schmidt, F Roessner, M Berger… - Journal of Thoracic …, 2019 - journals.lww.com
Objectives: Left ventricular (LV) hypertrophy in resistant hypertensive patients is associated
with a reduced intramyocardial perfusion. Renal sympathetic denervation (RDN) has been …

Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult-to-control hypertensive patients: prospective case series

F Mahfoud, M Böhm, LC Rump, O Vonend… - …, 2013 - Am Heart Assoc
In disagreement with several other studies, the authors report no significant overall blood BP
lowering effect after RDN in a small group of 12 patients, and not surprisingly did not …

Heart and kidneys: Renal denervation as therapy for hypertension

F Mahfoud, D Linz, M Böhm - Herz, 2013 - Springer
Die arterielle Hypertonie gehört in den westlichen Industrienationen mit ihrer hohen
Prävalenz zu den häufigsten chronischen Erkrankungen und ist ein Hauptrisikofaktor für …

High incidence of secondary hypertension in patients referred for renal denervation–the Copenhagen experience

LK Olsen, AL Kamper, JH Svendsen, LE Bang… - Blood …, 2014 - Taylor & Francis
Percutaneous renal denervation is a new treatment option for patients with resistant
hypertension and little is known about the eligibility of patients referred. 100 consecutive …

[HTML][HTML] Research needs in the area of device-related treatments for hypertension

J Jordan, JF Mann, FC Luft - Kidney International, 2013 - Elsevier
Hypertension is the primary risk factor for cardiovascular and renal-disease endpoints.
Medications help many patients but not all. Recently, two device-related treatments have …